Impact of granting a Conditional Marketing Authorisation for Pfizer-BioNTech COVID-19 vaccine (Comirnaty®)

Document first published:
Page updated:
Topic:
,
Publication type:

This letter draws attention to a number of operational implications for the management of the Pfizer-BioNTech vaccines and asks for appropriate steps to be taken to make relevant colleagues aware.

Link

Impact of granting a Conditional Marketing Authorisation for Pfizer-BioNTech COVID-19 vaccine (Comirnaty®)

Impact of granting a Conditional Marketing Authorisation for Pfizer-BioNTech COVID-19 vaccine (Comirnaty®)

NHS England is not responsible for content on external websites.

Summary

Letter from Dr Keith Ridge CBE, Chief Pharmaceutical Officer for England.

Published 26 August 2021.

Document

Impact of granting a Conditional Marketing Authorisation for Pfizer-BioNTech COVID-19 vaccine (Comirnaty®)

Impact of granting a Conditional Marketing Authorisation for Pfizer-BioNTech COVID-19 vaccine (Comirnaty®)

  • PDF
  • 82 KB
  • 3 pages

Summary

Letter from Dr Keith Ridge CBE, Chief Pharmaceutical Officer for England.

Published 26 August 2021.